S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder

An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine

Jonathan E. Alpert, George Papakostas, David Mischoulon, John J. Worthington, Timothy Petersen, Yasmin Mahal, Alana Burns, Teodoro Bottiglieri, Andrew A. Nierenberg, Maurizio Fava

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.

Original languageEnglish (US)
Pages (from-to)661-664
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume24
Issue number6
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

S-Adenosylmethionine
Major Depressive Disorder
Serotonin Uptake Inhibitors
Antidepressive Agents
Depression
Headache
Outpatients
Placebos
Safety
Venlafaxine Hydrochloride

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder : An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. / Alpert, Jonathan E.; Papakostas, George; Mischoulon, David; Worthington, John J.; Petersen, Timothy; Mahal, Yasmin; Burns, Alana; Bottiglieri, Teodoro; Nierenberg, Andrew A.; Fava, Maurizio.

In: Journal of Clinical Psychopharmacology, Vol. 24, No. 6, 12.2004, p. 661-664.

Research output: Contribution to journalArticle

Alpert, Jonathan E. ; Papakostas, George ; Mischoulon, David ; Worthington, John J. ; Petersen, Timothy ; Mahal, Yasmin ; Burns, Alana ; Bottiglieri, Teodoro ; Nierenberg, Andrew A. ; Fava, Maurizio. / S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder : An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. In: Journal of Clinical Psychopharmacology. 2004 ; Vol. 24, No. 6. pp. 661-664.
@article{49a80b9375a6416f9bca159409f48a97,
title = "S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine",
abstract = "Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50{\%} and a remission rate of 43{\%} following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.",
author = "Alpert, {Jonathan E.} and George Papakostas and David Mischoulon and Worthington, {John J.} and Timothy Petersen and Yasmin Mahal and Alana Burns and Teodoro Bottiglieri and Nierenberg, {Andrew A.} and Maurizio Fava",
year = "2004",
month = "12",
doi = "10.1097/01.jcp.0000145339.45794.cd",
language = "English (US)",
volume = "24",
pages = "661--664",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder

T2 - An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine

AU - Alpert, Jonathan E.

AU - Papakostas, George

AU - Mischoulon, David

AU - Worthington, John J.

AU - Petersen, Timothy

AU - Mahal, Yasmin

AU - Burns, Alana

AU - Bottiglieri, Teodoro

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

PY - 2004/12

Y1 - 2004/12

N2 - Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.

AB - Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.

UR - http://www.scopus.com/inward/record.url?scp=8744287602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744287602&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000145339.45794.cd

DO - 10.1097/01.jcp.0000145339.45794.cd

M3 - Article

VL - 24

SP - 661

EP - 664

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -